(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |
|---|---|---|---|---|---|---|---|
| 1xbb | STI | Imatinib (DB00619) | Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. | TYROSINE-PROTEIN KINASE SYK (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 2gqg | 1N1 | Dasatinib (DB01254) | Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 2ivu | ZD6 | Vandetanib (DB05294) | Vandetanib is an antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET PRECURSOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 2oiq | STI | Imatinib (DB00619) | Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus) | PK_Tyr_Ser-Thr | ||
| 2pl0 | STI | Imatinib (DB00619) | Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 2yfx | VGH | Crizotinib (DB08865) | Crizotinib is a receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. | TYROSINE-PROTEIN KINASE RECEPTOR (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 2zva | 1N1 | Dasatinib (DB01254) | Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. | TYROSINE-PROTEIN KINASE LYN (Mus musculus) | PK_Tyr_Ser-Thr | ||
| 3bbt | FMM | Lapatinib (DB01259) | Lapatinib is an antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-negative breast cancer in patients who received prior chemotherapeutic treatments. | RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3eyg | MI1 | Tofacitinib (DB08895) | Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid and psoriatic arthritis, and ulcerative colitis. It is not recommended to be combined with biologic therapies or potent immunosuppressants like cyclosporine or azathioprine. | TYROSINE-PROTEIN KINASE (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3fup | MI1 | Tofacitinib (DB08895) | Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid and psoriatic arthritis, and ulcerative colitis. It is not recommended to be combined with biologic therapies or potent immunosuppressants like cyclosporine or azathioprine. | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3g5d | 1N1 | Dasatinib (DB01254) | Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus) | PK_Tyr_Ser-Thr | ||
| 3gvu | STI | Imatinib (DB00619) | Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. | TYROSINE-PROTEIN KINASE ABL2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3ik3 | 0LI | Ponatinib (DB08901) | Ponatinib is a kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML). | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus) | PK_Tyr_Ser-Thr | ||
| 3k54 | 1N1 | Dasatinib (DB01254) | Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. | TYROSINE-PROTEIN KINASE BTK (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3k5v | STI | Imatinib (DB00619) | Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. | TYROSINE-PROTEIN KINASE ABL1 (Mus musculus) | PK_Tyr_Ser-Thr | ||
| 3lxk | MI1 | Tofacitinib (DB08895) | Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid and psoriatic arthritis, and ulcerative colitis. It is not recommended to be combined with biologic therapies or potent immunosuppressants like cyclosporine or azathioprine. | TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3lxn | MI1 | Tofacitinib (DB08895) | Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid and psoriatic arthritis, and ulcerative colitis. It is not recommended to be combined with biologic therapies or potent immunosuppressants like cyclosporine or azathioprine. | NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3miy | B49 | Sunitinib (DB01268) | Sunitinib is a receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). | TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3sxr | 1N1 | Dasatinib (DB01254) | Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. | CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3ue4 | DB8 | Bosutinib (DB06616) | Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. | TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 3zbf | VGH | Crizotinib (DB08865) | Crizotinib is a receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 4mxo | DB8 | Bosutinib (DB06616) | Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 4uxl | 5P8 | Lorlatinib (DB12130) | Lorlatinib is an anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 4wa9 | AXI | Axitinib (DB06626) | Axitinib is an oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. | TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens) | NA | ||
| 5mo4 | NIL | Nilotinib (DB04868) | Nilotinib is a kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib. | TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens) | PK_Tyr_Ser-ThrSH2SH3_1 | ||
| 5p9i | 1E8 | Ibrutinib (DB09053) | Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. | TYROSINE-PROTEIN KINASE BTK (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6j6m | BA0 | Zanubrutinib (DB15035) | Zanubrutinib is a kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy. | TYROSINE-PROTEIN KINASE BTK (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6jqr | C6F | Gilteritinib (DB12141) | Gilteritinib is an AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia. | RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (NA) | PK_Tyr_Ser-Thr | ||
| 6l8l | 1E8 | Ibrutinib (DB09053) | Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus) | PK_Tyr_Ser-Thr | ||
| 6nec | XIN | Nintedanib (DB09079) | Nintedanib is a triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer. | PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6op9 | DB8 | Bosutinib (DB06616) | Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. | RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6tu9 | 0LI | Ponatinib (DB08901) | Ponatinib is a kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML). | INACTIVE TYROSINE-PROTEIN KINASE TRANSMEMBRANE RECEPTOR ROR1 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6vne | 2TA | Fedratinib (DB12500) | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was... | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6vsn | RG4 | Ruxolitinib (DB08877) | Ruxolitinib is a kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6wto | 3JW | Baricitinib (DB11817) | Baricitinib is a Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 7ab1 | C6F | Gilteritinib (DB12141) | Gilteritinib is an AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia. | TYROSINE-PROTEIN KINASE MER (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |